AA amyloidosis

Potential therapy with antisense oligonucleotides

B. Kluve-Beckerman, J. Hardwick, L. Du, Merrill Benson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Amyloid A (AA) patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We are investigating SAA-specific antisense oligonucleotides (ASOs) as a means to specifically suppress serum amyloid A (SAA) production and thereby slow amyloid deposition. Peak SAA levels induced during an acute inflammatory response were 65% lower in ASO-treated mice than in those given saline. To test ASO effect on amyloid deposition, mice were induced to develop amyloid (week 1) and then treated with ASO, 3×per week (weeks 2-5); a second inflammatory stimulus given at the start of week 5. Mice were sacrificed 1 week later and analyzed for amyloid deposition. Spleen, liver, intestine, and heart of all 7 ASO-treated mice contained significantly less amyloid than corresponding organs of 7 saline-treated controls. Other than tiny specks of amyloid, no obvious pathology was seen in mice treated with ASO.

Original languageEnglish
Pages (from-to)200-202
Number of pages3
JournalAmyloid
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2011

Fingerprint

Antisense Oligonucleotides
Amyloidosis
Amyloid
Serum Amyloid A Protein
Therapeutics
Intestines
Renal Insufficiency
Disease Progression
Spleen
Pathology
Inflammation
Liver
Infection

ASJC Scopus subject areas

  • Internal Medicine

Cite this

AA amyloidosis : Potential therapy with antisense oligonucleotides. / Kluve-Beckerman, B.; Hardwick, J.; Du, L.; Benson, Merrill.

In: Amyloid, Vol. 18, No. SUPPL. 1, 06.2011, p. 200-202.

Research output: Contribution to journalArticle

Kluve-Beckerman, B, Hardwick, J, Du, L & Benson, M 2011, 'AA amyloidosis: Potential therapy with antisense oligonucleotides', Amyloid, vol. 18, no. SUPPL. 1, pp. 200-202. https://doi.org/10.3109/13506129.2011.574354
Kluve-Beckerman, B. ; Hardwick, J. ; Du, L. ; Benson, Merrill. / AA amyloidosis : Potential therapy with antisense oligonucleotides. In: Amyloid. 2011 ; Vol. 18, No. SUPPL. 1. pp. 200-202.
@article{483c3d251f9e40b8a0601044f57b27c7,
title = "AA amyloidosis: Potential therapy with antisense oligonucleotides",
abstract = "Amyloid A (AA) patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We are investigating SAA-specific antisense oligonucleotides (ASOs) as a means to specifically suppress serum amyloid A (SAA) production and thereby slow amyloid deposition. Peak SAA levels induced during an acute inflammatory response were 65{\%} lower in ASO-treated mice than in those given saline. To test ASO effect on amyloid deposition, mice were induced to develop amyloid (week 1) and then treated with ASO, 3×per week (weeks 2-5); a second inflammatory stimulus given at the start of week 5. Mice were sacrificed 1 week later and analyzed for amyloid deposition. Spleen, liver, intestine, and heart of all 7 ASO-treated mice contained significantly less amyloid than corresponding organs of 7 saline-treated controls. Other than tiny specks of amyloid, no obvious pathology was seen in mice treated with ASO.",
author = "B. Kluve-Beckerman and J. Hardwick and L. Du and Merrill Benson",
year = "2011",
month = "6",
doi = "10.3109/13506129.2011.574354",
language = "English",
volume = "18",
pages = "200--202",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - AA amyloidosis

T2 - Potential therapy with antisense oligonucleotides

AU - Kluve-Beckerman, B.

AU - Hardwick, J.

AU - Du, L.

AU - Benson, Merrill

PY - 2011/6

Y1 - 2011/6

N2 - Amyloid A (AA) patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We are investigating SAA-specific antisense oligonucleotides (ASOs) as a means to specifically suppress serum amyloid A (SAA) production and thereby slow amyloid deposition. Peak SAA levels induced during an acute inflammatory response were 65% lower in ASO-treated mice than in those given saline. To test ASO effect on amyloid deposition, mice were induced to develop amyloid (week 1) and then treated with ASO, 3×per week (weeks 2-5); a second inflammatory stimulus given at the start of week 5. Mice were sacrificed 1 week later and analyzed for amyloid deposition. Spleen, liver, intestine, and heart of all 7 ASO-treated mice contained significantly less amyloid than corresponding organs of 7 saline-treated controls. Other than tiny specks of amyloid, no obvious pathology was seen in mice treated with ASO.

AB - Amyloid A (AA) patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We are investigating SAA-specific antisense oligonucleotides (ASOs) as a means to specifically suppress serum amyloid A (SAA) production and thereby slow amyloid deposition. Peak SAA levels induced during an acute inflammatory response were 65% lower in ASO-treated mice than in those given saline. To test ASO effect on amyloid deposition, mice were induced to develop amyloid (week 1) and then treated with ASO, 3×per week (weeks 2-5); a second inflammatory stimulus given at the start of week 5. Mice were sacrificed 1 week later and analyzed for amyloid deposition. Spleen, liver, intestine, and heart of all 7 ASO-treated mice contained significantly less amyloid than corresponding organs of 7 saline-treated controls. Other than tiny specks of amyloid, no obvious pathology was seen in mice treated with ASO.

UR - http://www.scopus.com/inward/record.url?scp=79959935277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959935277&partnerID=8YFLogxK

U2 - 10.3109/13506129.2011.574354

DO - 10.3109/13506129.2011.574354

M3 - Article

VL - 18

SP - 200

EP - 202

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - SUPPL. 1

ER -